The majority of the analyst ratings for Vertex Pharmaceuticals in the last quarter were bullish or somewhat bullish, indicating a positive outlook for the company. The average 12-month price target of $371.18, which has increased by 2.32% over the past month, suggests potential upside for the stock. This could have a positive impact on the company's stock price in the short term.